TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Refractory to or relapsed after at least 1 prior treatment regimen;~* Eastern Cooperative Oncology Group (ECOG) score of 0 to 2;~* At least 18 years of age.~Exclusion Criteria:~* Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ≥ 2 weeks);~* Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months;~* Known hepatitis B virus, hepatitis C virus or HIV infection;~* Previous therapy with GS-1101 (CAL-101), IPI-145 or any drug that specifically inhibits the PI3K or mTOR pathway;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TGR-1202 (Type: EXPERIMENTAL): TGR-1202 Daily Oral Dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~Dyslipidemic subject who is currently undergoing statin therapy and no change in lipid-lowering therapy or dose during the 4 week prior to randomization~Exclusion criteria:~1. Recent (i.e.,\<6 months prior to screening) CV event and/or vascular procedure defined as:~   A)ST-elevation MI or non-ST-elevation MI B)Unstable angina C)Coronary revascularization \[(percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)\] D)Stroke of any etiology E)Peripheral arterial disease with critical limb ischemia (resting pain or ischemic skin lesions, either ulcers or gangrene) F)Resuscitated cardiac arrest~2. Planned CABG or planned PCI or planned major non-cardiac surgery within study period~3. No measurable Lp-PLA2 activity in plasma (\<10 nmol/min/mL) at screening~4. Change in a lipid-lowering medication, regimen or dosage during the 4 week prior to randomization~5. Poorly controlled dyslipidemia (LDL-c \>=160 mg/dL) at screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Group (Type: PLACEBO_COMPARATOR): Matched Placebo
- SB480848 40mg Group (Type: EXPERIMENTAL): SB480848 40mg/day
- SB480848 80mg Group (Type: EXPERIMENTAL): SB480848 80mg/day
- SB480848 160mg Group (Type: EXPERIMENTAL): SB480848 160mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dosing Study of Replagal in Patients With Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Patients with Fabry disease participating in 00-N-0185/TKT011 or 02-N-0220/TKT015 may be eligible. No other Fabry patients will be eligible.~Patients losing GFR at a rate greater than 5 ml/min/year despite ERT with agalsidase alfa for greater than or equal to 2.5 years in 00-N-0185/TKT/003/006/011 Study or ERT over greater than or equal to 1.0 years in 02-N-0220/TKT/010/015 Study.~Patients who at least twice demonstrated significant improvement or normalization of sweat function (by QSART or thermoregulatory sweat test) or reduction in serum creatinine by at least 10% but return to the pre-infusion state before the subsequent biweekly enzyme infusion.~Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent.~EXCLUSION CRITERIA:~Patients with Fabry disease, who are not already part of 00-N-0185/TKT011 or 02-N-0220/TKT015.~Patients on these protocols who have stable serum creatinine (or a lesser rise in serum creatinine than stipulated in the inclusion criteria), and do not show other objective evidence of incomplete clinical response between biweekly infusions (e.g. sweat function).~Patients who have begun dialysis or who have received a renal transplant.~Patients who cannot tolerate the study procedures or who are unable or unwilling to travel to the study center as required by this protocol.~Patients with an intercurrent medical condition that would render them unsuitable for mthe study e.g. HIV, diabetes. The reason is that the pathologies of these conditions will be significant confounders in assessing the effect of the experimental therapy and its adverse events.~Patients who in the opinion of the investigator (for whatever reason) are thought to be unsuitable for the study.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Relagal (Type: EXPERIMENTAL): All participants received Relagal administered weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Training Attentional Awareness and Control in ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet established Diagnostic and Statistical Manual-5 (DSM-5) criteria for ADHD predominately inattentive or combined subtype with clinically significant levels of impairment, diagnosed by structured clinical interview, the Mini International Neuropsychiatric Interview, and corroborating information~2. Clinical Global Impression-Severity (CGI-S) score ≥ 4 for ADHD~3. No lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse, or substance dependence (except nicotine) as assessed with the Mini-International Neuropsychiatric Interview (MINI)~4. Able in the opinion of the investigator to complete all required study procedures.~Exclusion Criteria:~1. History of diagnosis of childhood disorder other than ADHD (e.g. autism, dyslexia)~2. History of any general medical condition likely to require chronic use of medication with identified Central Nervous System (CNS) effects suspected to alter cognitive performance~3. History of seizure disorder, brain tumor, other major neurological disorder or head injury resulting in loss of consciousness~4. Serious oxygen deprivation~5. Current psychopathology requiring ongoing treatment with antipsychotic medications, mood stabilizers, benzodiazepines, or anticonvulsants~6. Current untreated psychopathology which is rated to be primary in terms of severity (greater than ADHD severity)~7. Current treatment with guanfacine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Active - SAC (Type: EXPERIMENTAL): Behavioral learning by using the Sustained Attention Control (SAC) Method's mobile software to increase sustained attention skills and self-awareness of attention control.
- Control - Scrabble (Type: ACTIVE_COMPARATOR): Behavioral learning using the mobile software game Scrabble to exercise word processing and executive control functions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients at least 18 years of age, presenting with generalized anxiety disorder (GAD).~Exclusion Criteria:~* Any current and primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I diagnosis other than GAD. Patients diagnosed with major depressive disorder within the past 6 months -or- patients diagnosed with panic disorder, post-traumatic stress disorder, or an eating disorder within the past year -or- obsessive-compulsive disorder, bipolar affective disorder, psychosis factitious disorder, or somatoform disorders during their lifetime~* The presence of an Axis II disorder or history of antisocial behavior, which in the judgement of the investigator would interfere with compliance with study protocol~* Have previously completed or withdrawn from this study or any other study investigating duloxetine or have previously been treated with duloxetine~* History of alcohol or any psychoactive substance abuse or dependence (as defined in the DSM-IV-TR) within the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must agree to the study protocol and provide written informed consent~2. Outpatients ≥ 20 years of age, male or female~3. Patients with secondary functional MR (stage B and C) and LV dysfunction~   * Symptoms due to coronary ischemia or heart failure may be present but symptoms due to MR should be absent~  * Normal mitral valve leaflets and chords~  * Regional or global wall motion abnormalities with mild or severe tethering of leaflet~  * ERO \> 0.10 cm2~  * 25% \< LV ejection fraction \< 50%~4. Dyspnea of NYHA functional class II or III~5. Patients must be on stable, optimized dose of an ACE inhibitors or ARBs for at least 4 weeks prior to study entry~Exclusion Criteria:~1. History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drug~2. Known history of angioedema~3. Any evidence of structural mitral valve disease, including prolapse of mitral leaflets and rupture of chords or papillary muscles~4. Current acute decompensated heart failure or dyspnea of NYHA functional class IV~5. Medical history of hospitalization within 6 weeks~6. Symptomatic hypotension and/or a SBP \< 100 mmHg at screening~7. Estimated GFR \< 30 mL/min/1.73m2~8. Serum potassium \> 5 mmol/L at screening~9. Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt~10. Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months~11. Planned coronary revascularization or mitral valve intervention within 1 year~12. Heart transplantation or implantation of cardiac resynchronization therapy~13. History of severe pulmonary disease~14. Significant aortic valve disease~15. Primary aldosteronism~16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method~17. Pregnant or nursing (lactating) women~18. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 (Type: EXPERIMENTAL): LCZ696 for 12 months
- Valsartan (Type: ACTIVE_COMPARATOR): Valsartan for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years or older~* Hypertension~* Cognitive criteria: score either 10 or less out of 15 for the executive clock draw test 1 (CLOX1) or less than or equal to 1 standard deviation from the corresponding age specific mean on the immediate memory subtest~Exclusion Criteria:~* Intolerance to ACEI or ARB~* History of congestive heart failure~* History of diabetes mellitus~* History of stroke (less than 6 months)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Candesartan (Type: EXPERIMENTAL): Angiotensin Receptor Blocker
- Lisinopril (Type: EXPERIMENTAL): Angiotensin-Converting Enzyme (ACE) Inhibitor
- HCTZ (Type: ACTIVE_COMPARATOR): Hydrochlorothiazide (diuretic)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MW031 in PMO Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMD -4.0\<T-score ≤-2.5 at either the lumbar spine or total hip or femoral neck~* All subjects must have at least one of following additional the risk factors:history of fracture, parental history of hip fracture, increased bone turnover rate at screening, low body weight, elderly (age≥65year)，current smoker~* Postmenopausal is defined as \>2 years postmenopausal, which can be \>2 years of spontaneous amenorrhea, or bilateral oophorectomy \>2 years after surgery. If bilateral oophorectomy status is unknown, use follicle-stimulating hormone (FSH) levels \> 40 mIU/mL to confirm surgical postmenopausal status.~Exclusion Criteria:~* Bone/metabolic disease~* Hyperparathyroidism or hypoparathyroidism~* Thyroid condition: Hyperthyroidism or hypothyroidism~* Rheumatoid arthritis~* Malignant tumors~* Malabsorption syndrome~* Oral bisphosphonates

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MW031 (Type: EXPERIMENTAL): MW031 injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial, according to the investigator's assessment.
- placebo (Type: PLACEBO_COMPARATOR): Placebo was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients from EMR (electronic medical record) system in the primary care in Sweden~* Patients equal to or more than 18 years of age~* Starting treatment with liraglutide or sitagliptin from January 2010 to December 2013~* Minimum of 180 days of prior follow-up/history within the database before their index date~Exclusion Criteria:~* Patients with cancer, end stage liver disease, end stage renal failure (non-diabetes related)~* Female patients with gestational diabetes during pregnancy~* Patients with previous GLP-1 (glucagon-like peptide-1) or DPP-IV (dipeptidyl peptidase-4 ) inhibitor use, i.e. patients should be incretin naïve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide / Sitagliptin (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Men 18 years of age and older.~2. Able to speak, read and understand English.~3. Willing to participate in the study and voluntarily sign an informed consent document.~Exclusion criteria:~1. Subject or anyone in their household is currently employed by a marketing or marketing research company, and advertising agency or public relations firm, a pharmacy or pharmaceutical company, a manufacturer of medicines, a managed care or health insurance company as a healthcare professional or healthcare practice.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- tamsulosin hydrochloride (Type: EXPERIMENTAL): patients will take drug for 8 weeks in this exploratory study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Males~* Females who are highly unlikely to become pregnant~* Patients poorly controlled while taking one or two oral antidiabetic medications~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis~* Patient required insulin therapy within the prior 8 weeks~* Patient is on or has been taking Thiazolidinediones (TZDs) such as Actos® (pioglitazone) or Avandia® (rosiglitazone) or is on or has been taking Byetta® (exenatide) within the prior 12 weeks of the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day (Type: EXPERIMENTAL): None
- sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with confirmed diagnosis of CF~* Must have a CFTR gating mutation in at least 1 allele~* Aged 2 through 5 years at screening and Day 1~* Weight \>= 8 kg at screening and Day 1~* Hematology, serum chemistry, coagulation, and vital signs results at screening with no clinically significant abnormalities that would interfere with the study assessments, as judged by the investigator~Exclusion Criteria:~* History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant~* An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks before Day 1~* Abnormal liver function, at screening~* History of solid organ or hematological transplantation~* Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks before Day 1~* Participation in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 terminal half-lives before screening

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Ivacaftor (Type: EXPERIMENTAL): Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than \[\<\] 14 kilograms \[kg\]) or 75 mg (for participants weighing greater than or equal to \[\>=\] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study..~Part B: Ivacaftor 50 mg (for participants weighing \<14 kg) or 75 mg (for participants weighing \>=14 kg) q12h for 24 weeks during Part B of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults~* Presence of an active exacerbation of the ongoing COPD requiring hospitalization for treatment~* Subjects with a documented diagnosis of COPD C or D~* Current smokers or ex-smokers~* A documented history of at least one moderate or severe COPD exacerbation in the 12 months preceding the Screening Visit that required antibiotics and/or systemic corticosteroid.~* Current regular treatment for COPD (for at least 2 months prior to the Screening Visit.~Exclusion Criteria:~* Age less than 40 years old~* Current diagnosis of asthma~* Subjects who have already completed treatment for the current exacerbation of COPD~* Subjects currently requiring intensive care unit (ICU) and/or mechanical ventilation~* Received a course of PDE4, p38 or PDE3/4 inhibitors within their respective defined washout periods.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen 1 (Type: EXPERIMENTAL): Drug: BCT197 Dose 1, Day 1 to Day 5
- Regimen 2 (Type: EXPERIMENTAL): Drug: BCT197 Dose 2, Day 1 to Day 5
- Regimen 3 (Type: PLACEBO_COMPARATOR): Placebo Day 1 to Day 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete